A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs KN 035 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors 3D Medicines
- 27 Mar 2017 Planned End Date changed from 1 Sep 2017 to 1 Jan 2019.
- 27 Mar 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2018.
- 27 Mar 2017 Status changed from not yet recruiting to recruiting.